Biotechnology

A German biotech's novel in vivo CAR T platform uses DNA for durable tumor control, aiming to make advanced cancer therapy an off-the-shelf medicine.

The clinical-stage biotech adds seasoned veterans from Eli Lilly and Iovance to accelerate its promising DNA Damage Response pipeline toward commercialization.

Valitor's VLTR-559 shows superior durability in preclinical data, potentially slashing wet AMD treatment from monthly injections to just two per year.

A landmark partnership between Propella Group and TISTR aims to unlock Thailand's hidden scientific gems, creating a pipeline for global VCs.

A devastating infant liver disorder meets a potential breakthrough. Satellite Bio's novel cell therapy just received a critical FDA nod, paving the way for trials.

An ultra-rare disease affects thousands, but few are diagnosed. Now, a new alliance of industry and advocates is racing to solve the diagnostic puzzle.

The biopharma firm gets a significant non-dilutive cash infusion, bolstering its finances to advance a promising oncology pipeline without equity dilution.

With backing from Eli Lilly, Cabaletta Bio's $150M financing will accelerate its potentially curative cell therapies for autoimmune diseases.

GRIN Therapeutics expands its pivotal Phase 3 study for radiprodil to Europe, fueling hope for a first-ever targeted therapy for a rare neurological disorder.

Spanish CDMO ROIS acquires a major Phoenix facility from Bristol Myers Squibb, securing US drug supply chains and expanding its global footprint.

A new partnership aims to combat a deadly infant disease, highlighting the critical role of human milk and corporate advocacy in saving the most vulnerable lives.

Noema Pharma's investigational drug cendifensine not only cut hot flashes by 92% but also aided weight loss and mood, promising a new non-hormonal era.

With $2.5M in seed funding, Hamilton's Stoked Bio is using a novel AI platform to tackle the world's toughest diseases, from superbugs to brain cancer.

Diakonos Oncology's personalized therapy, DOC1021, reports impressive survival data in early trials for glioblastoma and pancreatic cancer.

Taiwan's SynbioTech is launching a science-backed probiotic portfolio at Vitafoods Europe, targeting a holistic approach to women's active aging.

With CHF 2.5 million in new seed funding, Swiss-based Oberland Biotech is set to tackle the competitive US and Asian nutritional food markets.

A new gene therapy has helped completely blind patients with Retinitis Pigmentosa regain light perception, offering hope to millions with inherited blindness.

Contineum Therapeutics reports encouraging early data for its non-opioid drug PIPE-791, offering a potential new weapon in the fight against chronic pain.

Biotech firm Ocubio adds commercial titan Jim Mazzo and clinical pioneer Dr. Eric Donnenfeld, signaling a major play to disrupt the ocular health market.

VectorBuilder tackles key AAV therapy hurdles in ophthalmology, aiming to boost consistency and unlock new treatments for blinding genetic diseases.